8.37
8.37 (0.60%)
As of Mar 03, 2023
Concert Pharmaceuticals, Inc. [CNCE]
Source:
Company Overview
Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that we discovered through the application of our DCE Platform
| Country | United States |
| Headquarters | lexington, massachusetts |
| Phone Number | 781-860-0045 |
| Industry | manufacturing |
| CEO | Roger D. Tung |
| Website | concertpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-29.6 |
| Net Income | $-28.9 |
| Net Cash | $-46.4 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -370,075 |
| Profit as % of Revenues | |
| Profit as % of Assets | -17.2% |
| Profit as % of Stockholder Equity | -21.7% |
Management Effectiveness
| Return on Equity | -21.7% |
| Return on Assets | -16.9% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $171.1 |
| Total Liabilities | $37.9 |
| Operating Cash Flow | $-83.2 |
| Investing Cash Flow | $-54.1 |
| Financing Cash Flow | $90.9 |
